VBIO Company Profile and Key Details

Valion Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended August 14, 2026, missed forecasts by -99.47%.

Average 10-day trading volume of 51.35 million shares is significantly above the 3-month average of 13.64 million, indicating heightened recent market interest.

Valion Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.03. This means the shares are trading above this model’s fair value.

Valuation shows Valion Bio, Inc. trading at a premium to the broader market with a P/E of -3.81. Our AI forecast model points to short-term weakness (-47.53% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Valion Bio, Inc. (NASDAQ:VBIO) closed at $0.19 USD, gaining $0.02 (11.59%) from the previous close of $0.17. The stock is currently mid-range between its 52-week high and low $0.16 and $3.66. With a market capitalization of about $789.35 thousand, Valion Bio, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.86). Key stats such as the average daily volume over the past year has been around 5.90 million shares, trading with heavier-than-usual volume. Headquartered in San Antonio, TX, Valion Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Michael R. Cavanaugh, the company employs approximately 52 people and listed since November 11, 2021. Valion Bio, Inc. operates as a late-stage biopharmaceutical company.

Our AI price prediction model suggests that Valion Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -47.53%, with price expected at $0.10 by August 28, 2026, within a range of $0.03 to $0.16 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by November 12, 2026, with a range of $0.00 to $0.01. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by August 13, 2027, within a range of $0.00 to $0.01.

Valion Bio, Inc. trades at a P/E ratio of -3.81, slightly below the S&P 500 average, with a price-to-sales ratio of 0.42 and a price-to-book ratio of 1.01 suggesting the stock is closer to book value. The P/FCF stands at -0.24, also above market averages.